Tarsal Tunnel Syndrome Drugs Segmentation
Drug Class (Corticosteroids, NSAIDs, Anticonvulsants, Opioids)
In terms of drug class, the corticosteroids segment is expected to dominate the tarsal tunnel syndrome drugs market with a share of 32.4% over the assessed timeframe. This segment’s leadership is pledged to its clinically proven higher efficacy as an anti-inflammatory and immunomodulatory agent. Several global health authorities have marked this medicine subtype as the first-line therapy for relieving compressed nerves. In this regard, a study conducted by NIH demonstrated 68.1-72.3% efficacy in reducing pain and swelling of the affected area within 2 weeks of the 1st dose. Furthermore, the recently introduced minimally invasive corticosteroid injections presented an 89.4% accuracy in targeted nerve sheath delivery, magnifying the interest of drug developers for further exploration in this segment.
Route of Administration (Oral, Injectable, Topical)
Based on the route of administration, the oral segment is predicted to hold the largest share of 28.5% in the tarsal tunnel syndrome drugs market by 2037. The worldwide utilization of this subtype is driven by its ability to offer patients convenience and a broader range of treatment options. This upsurging demand can also be displayed by the CDC report, calculating the proportion of oral medicines in the net neuropathic pain prescriptions to be over 60.4%. Moreover, their superiority in maintaining compliance and a greater safety profile makes this segment a priority for both drug producers and consumers. Furthermore, the segment’s proprietorship over other administration routes can also be testified by the steady capital influx in R&D, where around 220.2 million was dedicated to research on oral analgesics.
Our in-depth analysis of the global tarsal tunnel syndrome drugs market includes the following segments:
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
|
End user |
|
